Eli Lilly and Company has agreed to acquire Merida Biosciences for up to $2.875 billion in cash, adding a precision immunology platform designed to selectively eliminate disease-causing antibodies ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Deal helps Lilly expand immunology pipeline, diversify beyond obesity drugs Merida's lead drug candidate targets Graves' disease and thyroid eye disease Transaction valued at up to $2.88 billion in ...

Eli Lilly’s biotech buying spree continues as the pharma giant is planning to carry out its 13 th buyout of a biotech this year, agreeing to acquire Merida Biosciences, a developer of precision ...

Eli Lilly (LLY) has agreed to acquire Merida Biosciences for up to $2.875B in cash, including an upfront payment and contingent milestone payments. The deal is expected to close in Q4 2026, subject to ...